Section
Pipeline
Late-stage drugs with significant commercial implications
PipelineFiercePharma ↗
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
PipelineFiercePharma ↗
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
PipelineFiercePharma ↗
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
PipelineFierceBiotech ↗
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpo…
PipelineBriefing
EMA’s CHMP supports AstraZeneca’s SERD camizestrant despite FDA skepticism and endorses Novo Nordisk’s first o…
PipelineEndpoints News ↗
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejec…
Page 1
Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.